India readies 5 sites for Phase 3 Oxford-AstraZeneca vaccine trial
Author : Saipriya Iyer | Published Date : 2020-07-29
Phase 3 or late-stage clinical trial of the Oxford-AstraZeneca coronavirus vaccine is reportedly set to be conducted across 5 sites in India.
Additionally, Oxford and its partner, AstraZeneca, have chosen the Serum Institute of India to manufacture the COVID-19 vaccine, following the anticipated achievement of positive trial results. The data from the Phase 1 and 2 trials has already been published earlier in July.
As per reports, the DBT (Department of Biotechnology) plays a key role in vaccine development, including funding, facilitating regulatory clearances, and providing access to various networks in the country. Moreover, the Serum Institute of India (SSI) based in Pune has sought permission from the DCGI (Drugs Controller General of India) to conduct the Phase 2 and 3 clinical trials. The institute is planning to commence the manufacturing process of the potential vaccine prior to achieving the final results, in order to ensure wide availability with sizable volumes once it receives overall approvals.
Earlier on 20th July, scientists announced high safety and efficacy of the vaccine developed by the Oxford University, as it induced a strong immune response in the Phase 1 trial. The doses of the vaccine were offered to 1,077 healthy subjects between 18-55 years of age, at 5 hospitals in the UK.
According to the results from this 1st phase, the vaccine candidate has induced a strong antibody as well as T-cell immune responses for over 56 days. The T-cells can significantly safeguard people against the virus for several years. Scientists also have discovered that the immune response could be higher after the patient receives the 2nd dose.
The Phase 1 vaccine trial was conducted among a small group of people to examine its safety as well as the stimulation of the immune system. In the 2nd phase, children and the elderly were studied to evaluate its safety and immunogenicity. The vaccine was then administered to a large number of subjects in the 3rd phase.
Source credit:
About Author
Saipriya Iyer . .
Saipriya Iyer presently works as a content developer for fractovia.org. Having dabbled with the domain of content creation for nearly half a decade, she now boasts of an enviable portfolio, holding substantial experience in penning down pieces related to technology, finance, and a wide spectrum of other industry verticals. A qualified computer engineering graduate from the University of Pune, Saipriya can often be found leveraging her knowledge of software technology and electronics in her write-ups. She can be contacted at- [email protected] | https://twitter.com/saipriya_i
Related News
Hero MotoCorp under investigation by Ministry of Corporate Affairs
The Indian Ministry of Corporate Affairs has reportedly ordered a probe into Hero MotoCorp to examine its association with an external vendor regarding alleged fund diversion. The objective of the investigation, conducted in the "public interest," is to evaluate the Hero MotoCorp owners... Read More>>
UK: Residents receive bills of up to £49,000 after Ovo acquires SSE
Customers of Ovo, the energy supplier were reportedly left shocked when they received energy bills of up to £49,000, due to data errors that led to overinflated energy bills for some residents. Ovo accepted that some of its customers have been affected by erroneous meter readings, and it bl... Read More>>
Bob Iger returns to Disney as CEO less than a year post retirement
Bob Iger, the ex-CEO of Walt Disney Co., is reportedly coming back to the mass media giant less than a year after his retirement. The surprise announcement comes at a time when Disney is struggling to earn profits from its streaming TV services. According to a statement released by Disney late Su... Read More>>